{"text": "citi analyst raised pt mrus 47 was 38 buy petosemtamab ph1 2 expansion abstract is undoubtedly very impressive the reported 36 orr is trending well above the historical cetuximab data which showed a 13 orr in pts who only failed platinum citi contends that bmy lly mrk"}
{"text": "mrus svb raised pt mrus 48 was 35 op after aacr ph1 2 abstract for merus petosemtamab showed robust efficacy validating previous efficacy signal in a larger number of pts merus provided regulatory update indicating that it met w fda in end of phase meeting bmy lly mrk"}
{"text": "guggenheim raised pt mrus 45 was 38 buy after co s aacr abstracts for upcoming petosemtamab presentations calls 36 orr and six months mdor w clean safety in 42 hnscc pts compelling and de risking to regulatory path bmy lly mrk"}
{"text": "looking at bmy off the stratsoldier easy setup scanner only on thestrat"}
{"text": "trading plan for today monday 4 17 2023 spy spy support 411 21 410 3 409 16 resistance 413 44 415 12 417 27 qqq qqq support 317 4 316 64 315 6 open gap at 313 7 resistance 318 6 319 2 320 34 open positions long bmy amzn msft aapl sbux meta short tsla"}
{"text": "bmy bristol myers regulatory applications accepted across three regions globally for abecma for earlier use in"}
